Titan Pharmaceuticals Inc.
http://www.titanpharm.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Titan Pharmaceuticals Inc.
Torrent On Acquisition And Licensing Strategy, Vonoprazan Trajectory
Amid deals activity in India, Torrent Pharma executives spelt out their acquisition expectations and licensing strategy while an in-licensed Takeda brand did well in Q1 of FY25. The US growth trajectory is seen determined by five to ten product approvals expected this fiscal
McKinsey Exec On Where India Innovation Could Head, Leveraging Pharma’s GCC Ecosystem
McKinsey & Company’s senior partner and lead, life sciences practice (Asia), talks to Scrip about innovation niches that could interest Indian firms including the ADC space, using AI to increase confidence in research activities and how India could leverage big pharma’s expanding global capability centres (GCCs) to shape the wider R&D ecosystem.
Zydus Marks Biosimilar Entry Into Mexico With Bevacizumab Approval
Marketed as Bhava, Zydus’ bevacizumab rival to Roche’s Avastin begins the firm’s biosimilar journey in the Latin American country.
Zydus’s ‘Transparency Failure’ Leads To Block On Indian Perjeta Biosimilar
“The principles of fairness in procedural conduct, especially in commercial disputes, is crucial,” Delhi’s High Court told Zydus Lifesciences as it agreed to temporarily block the sale of the firm’s recently launched biosimilar to Roche’s Perjeta.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Controlled Release
-
Drug Delivery
-
Medical Devices
- Implantable Devices
- Other Names / Subsidiaries
-
- Titan
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice